Bronchodilator Drugs - APAC
APAC- Revenue in the Bronchodilator Drugs market is projected to reach US$6.17bn in 2024.
- Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 4.18%, resulting in a market volume of US$7.27bn by 2028.
- In global comparison, most revenue will be generated United States (US$17.34bn in 2024).
- Key regions:
- United States,
- Europe,
- Brazil,
- Japan,
- United Kingdom
Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.
Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).
Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim
In-Scope
- Short-term and long-term bronchodilators
- Treatment of asthma and COPD
- Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
- Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid
Out-Of-Scope
- Other drugs to treat asthma or COPD
- Smoking cessation products
- Alternative medicine
